Vera Therapeutics, Inc. (NASDAQ:VERA) Shares Purchased by Nicholas Investment Partners LP

Nicholas Investment Partners LP lifted its holdings in shares of Vera Therapeutics, Inc. (NASDAQ:VERA) by 49.3% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 106,805 shares of the company’s stock after purchasing an additional 35,246 shares during the quarter. Nicholas Investment Partners LP owned about 0.17% of Vera Therapeutics worth $4,517,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in VERA. Avoro Capital Advisors LLC raised its holdings in Vera Therapeutics by 30.2% during the fourth quarter. Avoro Capital Advisors LLC now owns 5,610,000 shares of the company’s stock worth $237,247,000 after purchasing an additional 1,300,410 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its holdings in Vera Therapeutics by 11.1% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 4,377,049 shares of the company’s stock valued at $185,107,000 after acquiring an additional 437,940 shares during the period. FMR LLC boosted its stake in shares of Vera Therapeutics by 9.6% during the 4th quarter. FMR LLC now owns 3,053,126 shares of the company’s stock worth $129,117,000 after acquiring an additional 267,842 shares in the last quarter. Vanguard Group Inc. raised its position in Vera Therapeutics by 14.3% during the fourth quarter. Vanguard Group Inc. now owns 2,949,564 shares of the company’s stock worth $124,737,000 after acquiring an additional 369,387 shares during the last quarter. Finally, T. Rowe Price Investment Management Inc. raised its holdings in shares of Vera Therapeutics by 43.8% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 1,415,179 shares of the company’s stock worth $59,848,000 after acquiring an additional 431,178 shares during the last quarter. Hedge funds and other institutional investors own 99.21% of the company’s stock.

Analyst Upgrades and Downgrades

VERA has been the topic of several research reports. Guggenheim raised their price target on shares of Vera Therapeutics from $59.00 to $61.00 and gave the company a “buy” rating in a report on Thursday, February 27th. Wolfe Research initiated coverage on shares of Vera Therapeutics in a research report on Tuesday, February 4th. They issued an “outperform” rating and a $49.00 target price for the company. Wedbush dropped their price target on shares of Vera Therapeutics from $34.00 to $26.00 and set a “neutral” rating on the stock in a research report on Wednesday, May 7th. HC Wainwright assumed coverage on Vera Therapeutics in a report on Monday, May 5th. They issued a “buy” rating and a $75.00 target price for the company. Finally, Cantor Fitzgerald reduced their price target on Vera Therapeutics from $107.00 to $100.00 and set an “overweight” rating for the company in a report on Wednesday, May 7th. One research analyst has rated the stock with a hold rating, seven have issued a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $63.33.

Vera Therapeutics Stock Down 4.0%

VERA stock opened at $21.58 on Wednesday. Vera Therapeutics, Inc. has a fifty-two week low of $18.53 and a fifty-two week high of $51.61. The stock has a market capitalization of $1.38 billion, a price-to-earnings ratio of -8.27 and a beta of 1.28. The business’s fifty day moving average price is $23.92 and its two-hundred day moving average price is $34.43. The company has a debt-to-equity ratio of 0.17, a current ratio of 13.76 and a quick ratio of 13.76.

Vera Therapeutics (NASDAQ:VERA) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.81) earnings per share for the quarter, missing the consensus estimate of ($0.75) by ($0.06). During the same quarter in the prior year, the business earned ($0.56) earnings per share. On average, equities analysts anticipate that Vera Therapeutics, Inc. will post -2.89 earnings per share for the current year.

Vera Therapeutics Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.